Global pharmaceutical stocks plummeted following President Trump's announcement of plans to reduce US prescription drug prices to match international levels. European companies like Novo Nordisk, AstraZeneca, and Roche experienced significant losses, mirroring declines in Asian and US markets. Eli Lilly, Pfizer, Bristol-Myers Squibb, and Merck all saw premarket share drops, fueled by concerns over reduced profitability.

Prepared by Christopher Adams and reviewed by editorial team.